secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001437749-24-033729
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma awarded second patent for ET-400; PDUFA target Feb 28, 2025
-----------------------------------------------------------------------

- USPTO granted U.S. Patent No. 12,133,914 for ET-400 (liquid hydrocortisone), expiring 2043.
- Second patent for ET-400; first patent (US 11,904,046) obtained in February 2024.
- Additional U.S. patent application for ET-400 remains under review.
- FDA NDA accepted with PDUFA target action date of February 28, 2025.
- If approved, ET-400 would be the only FDA-approved liquid hydrocortisone formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924033729/0001437749-24-033729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924033729/eton20241105_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-033729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer